AU · rank #16 · 2026-10-20
PGEN
NASDAQ · $2.67B (USD)
The exact numbers the algorithm saw.
| Composite score Z-score blend of all factors below. | 1.227 |
|---|---|
| EPS revisions (30d) Change in consensus EPS estimate over the past 30 days ($/share). | -$0.05 |
| Net revisions (30d) Number of analysts revising upward minus downward. | 2 |
| Insider signal (90d) $24,662 across 1 unique buyers. | 1.465 |
| Analyst upside Consensus target $13.65 | +105.0% |
| Momentum acceleration 3-month minus 12-month momentum. | +7.93% |
| Analyst rating 5 = Strong Buy, 1 = Strong Sell. | 4.25 |
| Gross margin TTM | +53.0% |
| 52w high | $8.98 |
| Market cap (USD) | $2.67B |
The AI research card
Independent qualitative review of each pick before the order is placed. On the rare day the research service is unavailable, the paper book trades on the quant ranking alone and no card appears here.
Summary
Precigen is a commercial-stage biopharmaceutical company commercializing PAPZIMEOS for adult recurrent respiratory papillomatosis (RRP) and developing AdenoVerse-based immunotherapies for HPV-associated cancers.
Rationale
The 105% analyst upside target and 4.25 rating are reinforced by PAPZIMEOS's commercial acceleration to $55.0M in Q2 2026 revenue, delivering a 475% earnings surprise and a path to cash-flow break-even.
Material risks
- 1Extreme commercial concentration in PAPZIMEOS leaves revenue targets vulnerable to adoption delays or future market-share erosion from INOVIO's investigational INO-3107.
- 2A tight liquidity buffer of $38.7M in cash versus $93.9M in long-term debt exposes the company to dilution or refinancing risk if commercial growth slows.
AI verdict council
Each pick is reviewed independently by 3 models before any order. 2 of 3 voted to proceed.